Clinical and anti-inflammatory effects of treating endotoxin-challenged pigs with meloxicam.
The clinical and anti-inflammatory effects of a single treatment of 0.4 mg meloxicam/kg bodyweight on pigs that had been challenged with Escherichia coli endotoxin were investigated. Significantly lower total clinical scores were recorded in pigs treated with meloxicam than in pigs treated with a placebo. Significantly higher mean serum concentrations of thromboxane B(2) were also recorded in pigs treated with a placebo for up to 24 hours after the challenge. The serum concentrations of acute phase proteins and specific antibody titres to E coli lipopolysaccharide were unaffected by the meloxicam. The meloxicam treatment was well tolerated.
Friton
G M
GM
Boehringer Ingelheim Animal Health, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany.
Schmidt
H
H
Schrödl
W
W
D000209:Acute-Phase Proteins / Q000032:analysis; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000907:Antibodies, Bacterial / Q000097:blood; D019446:Endotoxemia / Q000188:drug therapy / Q000662:veterinary*; D004926:Escherichia coli / Q000276:immunology; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000662:veterinary*; D005260:Female; D007074:Immunoglobulin G / Q000097:blood; D008070:Lipopolysaccharides / Q000276:immunology; D008297:Male; D000077239:Meloxicam; D016037:Single-Blind Method; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy*; D013843:Thiazines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000097:blood; D016896:Treatment Outcome
D000209:Acute-Phase Proteins; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000907:Antibodies, Bacterial; D007074:Immunoglobulin G; D008070:Lipopolysaccharides; D013843:Thiazines; D013844:Thiazoles; D013929:Thromboxane B2; D000077239:Meloxicam